ReviewAntiviral research2023
Influenza antivirals and their role in pandemic preparedness.
Review in Antiviral research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Associations of oseltamivir with neuropsychiatric and behavioral adverse events: A systematic review and meta-analysis.Journal of managed care & specialty pharmacy · 2025Pooled it
- A systematic literature review on public health and healthcare resources for pandemic preparedness planning.BMC public health · 2024Pooled it
- A bispecific antibody targeting conserved hemagglutinin epitopes confers broad protection against H7 avian influenza and accelerates viral clearance via localized respiratory delivery.Emerging microbes & infections · 2026Article
- A Cluster of Influenza A(H3N2) Viruses in 2024 From Tasmania, Australia, With Reduced Susceptibility to Baloxavir.Influenza and other respiratory viruses · 2026Article
- A Sequence-Based Update on Amino Acid Substitutions in Influenza Polymerase Acidic Protein in Europe That Alter Baloxavir Susceptibility From 2009 to 2025.Influenza and other respiratory viruses · 2026Article
- Phellinus pini Polysaccharides Regulate Gut Microbiota-Host Metabolism to Attenuate Influenza-Driven Lung Injury.Current microbiology · 2026Article
- DNA Nanostructure-Templated Multivalency Enables Broad-Spectrum Virus Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- A Framework for Assessing the Opportunity for Advanced Research, Development, and Regulatory Approval of Medical Countermeasures: A Component of BARDA's Emerging Infectious Diseases Strategy.The Journal of infectious diseases · 2026Article
- From neuraminidase inhibitors to novel mechanisms: expanding therapeutic strategies against influenza.Frontiers in cellular and infection microbiology · 2026Review
- Artificial Intelligence in Pharmaceutical Drug Development: Transforming Formulation and Innovation.Current drug discovery technologies · 2026Review
- Development and application of a VNAR-based detection nanobody for avian influenza virus H9N2.Frontiers in immunology · 2026Article
- Efficacy and Safety of Anti-Influenza Drugs in 160 Chinese Children With Influenza A: A Retrospective Study.Journal of paediatrics and child health · 2026Article
- A Novel Recombinant Chicken-Derived H6N8 Subtype Avian Influenza Virus Caused Disease in Chickens and Mice.Viruses · 2025Article
- Plant-Derived Carotenoid Lutein Demonstrates Multifunctional Antiviral Activity against Influenza A VirusJournal of microbiology and biotechnology · 2025Article
- Divergent Avian Influenza H10 Viruses from Sympatric Waterbird Species in Italy: Zoonotic Potential Assessment by Molecular Markers.Microorganisms · 2025Article
- Genetic characteristics of influenza A/H3N2 virus in Jiaxing, China (2019-2024).Virology journal · 2025Article
- Chinese Medicine Strategies for Influenza A: Research Progress and Prospects.Chinese journal of integrative medicine · 2025Review
- Influenza virus infection reprograms cholesterol biosynthesis to facilitate virus replication by the TAK1-RORγ axis.PLoS pathogens · 2025Article
- Novel Mechanism of the L-Type Voltage-Gated Channels/Calpains Axis in Influenza A Virus-Induced Autophagosome Activity.Journal of medical virology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Effective antivirals provide crucial benefits during the early phase of an influenza pandemic, when vaccines are still being developed and manufactured. Currently, two classes of viral protein-targeting drugs, neuraminidase inhibitors and polymerase inhibitors, are approved for influenza treatment and post-exposure prophylaxis. Resistance to both classes has been documented, highlighting the need to develop novel antiviral options that may include both viral and host-targeted inhibitors. Such efforts will form the basis of management of seasonal influenza infections and of strategic planning for future influenza pandemics. This review focuses on the two classes of approved antivirals, their drawbacks, and ongoing work to characterize novel agents or combination therapy approaches to address these shortcomings. The importance of these topics in the ongoing process of influenza pandemic planning is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.